Subscribe To
We now know what budweiser will do with the beer it can't sell at the world cup
Qatar's last-minute decision to ban alcohol at World Cup stadiums has left Budweiser with loads of beer...
November 22, 2022, 5:04 pm
Medtronic plc (mdt) q2 2023 earnings call transcript
Medtronic plc (NYSE:MDT ) Q2 2023 Earnings Conference Call November 22, 2022 8:00 AM ET Company Participants Ryan W...
November 22, 2022, 12:55 pm
Zto express (cayman) inc. (zto) q3 2022 - earnings call transcript
ZTO Express (Cayman) Inc. (NYSE:ZTO ) Q3 2022 Earnings Conference Call November 21, 2022 7:30 PM ET Company Participants Sophie Li - Capital Markets D...
November 21, 2022, 11:35 pm
Jonathan randall named president of mack trucks north america
Jonathan Randall, in charge of North American sales and global operations for Mack Trucks, has been named North American president of the Volvo Group ...
November 21, 2022, 3:40 pm
eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "...
November 20, 2022, 6:30 pm
eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "...
November 20, 2022, 6:30 pm
eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "...
November 20, 2022, 6:30 pm
eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "...
November 20, 2022, 6:30 pm
eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "...
November 20, 2022, 6:30 pm
eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "...
November 20, 2022, 6:30 pm
eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "...
November 20, 2022, 6:30 pm
eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "...
November 20, 2022, 6:30 pm
eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "...
November 20, 2022, 6:30 pm
eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "...
November 20, 2022, 6:30 pm
eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "...
November 20, 2022, 6:30 pm
eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "...
November 20, 2022, 6:30 pm
eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "...
November 20, 2022, 6:30 pm
eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "...
November 20, 2022, 6:30 pm
eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "...
November 20, 2022, 6:30 pm
eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen
TOKYO , Nov. 20, 2022 /PRNewswire/ -- eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "...
November 20, 2022, 6:30 pm